• MJHLS Brand Logo

© 2021 MJH Life Sciences™ and Optometry Times. All rights reserved.

Viewpoints

Updates: Diabetic macular edema and diabetic retinopathy

EP. 1: Updates in diabetic macular edema, diabetic retinopathy
EP. 1: Updates in diabetic macular edema, diabetic retinopathy
EP. 2: Diabetic Retinopathy imaging
EP. 2: Diabetic Retinopathy imaging
EP. 3: Using OCT-A for patients with diabetes
EP. 3: Using OCT-A for patients with diabetes
EP. 4: Optimize diabetes health management
EP. 4: Optimize diabetes health management
EP. 5: Diabetes management: OD and MD communication
EP. 5: Diabetes management: OD and MD communication
EP. 6: Diabetes management challenges
EP. 6: Diabetes management challenges
EP. 7: ADA guidelines for managing DR/DME
EP. 7: ADA guidelines for managing DR/DME
EP. 8: DR/DME treatment options
EP. 8: DR/DME treatment options
EP. 9: COVID-19 impact on management of DR/DME
EP. 9: COVID-19 impact on management of DR/DME
EP. 10: Emerging treatment options for DR/DME
EP. 10: Emerging treatment options for DR/DME

Advancements in dry eye managment

EP. 1: Introduction and overview
EP. 1: Introduction and overview
EP. 2: Consequences and epidemiology of untreated dry eye
EP. 2: Consequences and epidemiology of untreated dry eye
EP. 3: Diagnosis and overlooking asymptomatic patients with DED
EP. 3: Diagnosis and overlooking asymptomatic patients with DED
EP. 4: Standard testing and assessment for DED
EP. 4: Standard testing and assessment for DED
EP. 5: General Principles of Treatment of DED
EP. 5: General Principles of Treatment of DED
EP. 6: OD and MD communication for optimal care
EP. 6: OD and MD communication for optimal care
EP. 7: Review of artificial tears for DED
EP. 7: Review of artificial tears for DED
EP. 8: Corticosteroids and Immunomodulators for the treatment of dry eye
EP. 8: Corticosteroids and Immunomodulators for the treatment of dry eye
EP. 9: The role of nutritional supplements and antibiotics in DED
EP. 9: The role of nutritional supplements and antibiotics in DED
EP. 10: How to treat meibomian gland dysfunction
EP. 10: How to treat meibomian gland dysfunction
EP. 11: In-office procedures and patient resistance for DED treatments
EP. 11: In-office procedures and patient resistance for DED treatments
EP. 12: Treatments for aqueous dry eye
EP. 12: Treatments for aqueous dry eye
EP. 13: Challenges in the management of DED
EP. 13: Challenges in the management of DED
EP. 14: Counseling and formulary concerns for DED therapies
EP. 14: Counseling and formulary concerns for DED therapies
EP. 15: Overlapping diseases and COVID-19's impact
EP. 15: Overlapping diseases and COVID-19's impact
EP. 16: Agents in the pipeline for DED
EP. 16: Agents in the pipeline for DED
EP. 17: Novel agents in the pipeline for DED
EP. 17: Novel agents in the pipeline for DED

Branded vs generics: You make the call in dry eye

EP. 1: Generic vs. Branded Ophthalmic Medications
EP. 1: Generic vs. Branded Ophthalmic Medications
EP. 2: Cost and Substitution Issues
EP. 2: Cost and Substitution Issues
EP. 3: Patient Counseling on Generic vs. Branded
EP. 3: Patient Counseling on Generic vs. Branded
EP. 4: Dry Eye Disease Epidemiology
EP. 4: Dry Eye Disease Epidemiology
EP. 5: Impact of Dry Eye on Surgical Outcome; Patient Screening
EP. 5: Impact of Dry Eye on Surgical Outcome; Patient Screening
EP. 6: Glaucoma Medications and Dry Eye Disease
EP. 6: Glaucoma Medications and Dry Eye Disease
EP. 7: Initiating Anti-Inflammatory/Immunomodulatory Therapy
EP. 7: Initiating Anti-Inflammatory/Immunomodulatory Therapy
EP. 8: Cyclosporine Formulation Challenges
EP. 8: Cyclosporine Formulation Challenges
EP. 9: Lifitegrast Experience and Patient Counseling
EP. 9: Lifitegrast Experience and Patient Counseling
EP. 10: Role of the Technician
EP. 10: Role of the Technician
EP. 11: The Technician’s Role
EP. 11: The Technician’s Role